Skip to main content
Premium Trial:

Request an Annual Quote

New Dutch IVD Shop to Use Agilent Arrays in Breast-Cancer Project

NEW YORK, Aug. 21 (GenomeWeb News) - A new in vitro diagnostics company created by the authors of two important breast-cancer studies will use Agilent Technologies' microarray platform in its cancer research, the firms said today.


The company, Agendia, said it hopes to use the technology to develop the first microarray-based diagnostic to "predict the aggressiveness" of breast cancer tumors.


Because researchers are not allowed to use microarrays as diagnostic tools in the United States, Agendia, based in The Netherlands, said it will handle the microarray analysis of all tumor samples in its own country.

Agendia was founded by researchers from the Netherlands Cancer Institute, in Amsterdam, who co-authored a set of landmark breast-cancer studies reported last year in the New England Journal of Medicine and Nature. The Institute, together with Rosetta Inpharmatics, a wholly owned subsidiary of Merck, performed this research using Agilent arrays and tissue samples.

In those studies, researchers identified gene-expression patterns that "correlate to aggressive tumors" as well as to tumors less likely to spread, according to Agendia. Though preliminary, that research showed that gene-expression data "has the potential" to help physicians better target cancer therapeutic regimens.

Agendia said it plans to develop microarray-based tests for a host of diseases beside breast cancer.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.